JP2023055809A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023055809A5 JP2023055809A5 JP2023011523A JP2023011523A JP2023055809A5 JP 2023055809 A5 JP2023055809 A5 JP 2023055809A5 JP 2023011523 A JP2023011523 A JP 2023011523A JP 2023011523 A JP2023011523 A JP 2023011523A JP 2023055809 A5 JP2023055809 A5 JP 2023055809A5
- Authority
- JP
- Japan
- Prior art keywords
- trans
- cancer
- vector
- cell
- rna molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 62
- 239000013598 vector Substances 0.000 claims description 42
- 210000004027 cell Anatomy 0.000 claims description 36
- 239000013603 viral vector Substances 0.000 claims description 22
- 108090000623 proteins and genes Proteins 0.000 claims description 20
- 201000010099 disease Diseases 0.000 claims description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 17
- 239000002773 nucleotide Substances 0.000 claims description 13
- 125000003729 nucleotide group Chemical group 0.000 claims description 13
- 241000700605 Viruses Species 0.000 claims description 10
- 102000004169 proteins and genes Human genes 0.000 claims description 10
- 102000018832 Cytochromes Human genes 0.000 claims description 8
- 108010052832 Cytochromes Proteins 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 8
- 239000000090 biomarker Substances 0.000 claims description 8
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims description 8
- 108020004707 nucleic acids Proteins 0.000 claims description 8
- 102000039446 nucleic acids Human genes 0.000 claims description 8
- 150000007523 nucleic acids Chemical class 0.000 claims description 8
- 108020004414 DNA Proteins 0.000 claims description 7
- 239000013612 plasmid Substances 0.000 claims description 7
- 206010010144 Completed suicide Diseases 0.000 claims description 6
- 241000700584 Simplexvirus Species 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 230000000295 complement effect Effects 0.000 claims description 6
- 238000001727 in vivo Methods 0.000 claims description 5
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 4
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 4
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 4
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 4
- 208000035143 Bacterial infection Diseases 0.000 claims description 4
- 241000701022 Cytomegalovirus Species 0.000 claims description 4
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 claims description 4
- 208000031886 HIV Infections Diseases 0.000 claims description 4
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims description 4
- 208000026350 Inborn Genetic disease Diseases 0.000 claims description 4
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 4
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 4
- 208000036142 Viral infection Diseases 0.000 claims description 4
- 230000002159 abnormal effect Effects 0.000 claims description 4
- 125000004266 aziridin-1-yl group Chemical group [H]C1([H])N(*)C1([H])[H] 0.000 claims description 4
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 4
- 229960004397 cyclophosphamide Drugs 0.000 claims description 4
- 229940104302 cytosine Drugs 0.000 claims description 4
- 229960004413 flucytosine Drugs 0.000 claims description 4
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 claims description 4
- 229960002963 ganciclovir Drugs 0.000 claims description 4
- 208000016361 genetic disease Diseases 0.000 claims description 4
- 201000009277 hairy cell leukemia Diseases 0.000 claims description 4
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 4
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 4
- 229960001101 ifosfamide Drugs 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- 229920000642 polymer Polymers 0.000 claims description 4
- 125000006850 spacer group Chemical group 0.000 claims description 4
- 230000001131 transforming effect Effects 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 208000009746 Adult T-Cell Leukemia-Lymphoma Diseases 0.000 claims description 2
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 claims description 2
- 206010061424 Anal cancer Diseases 0.000 claims description 2
- 208000007860 Anus Neoplasms Diseases 0.000 claims description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 241000894006 Bacteria Species 0.000 claims description 2
- 241001518086 Bartonella henselae Species 0.000 claims description 2
- 206010004146 Basal cell carcinoma Diseases 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010005949 Bone cancer Diseases 0.000 claims description 2
- 208000018084 Bone neoplasm Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 241000589562 Brucella Species 0.000 claims description 2
- 102000053642 Catalytic RNA Human genes 0.000 claims description 2
- 108090000994 Catalytic RNA Proteins 0.000 claims description 2
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 claims description 2
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 2
- 102100022641 Coagulation factor IX Human genes 0.000 claims description 2
- 102100026735 Coagulation factor VIII Human genes 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 108020004635 Complementary DNA Proteins 0.000 claims description 2
- 241000702421 Dependoparvovirus Species 0.000 claims description 2
- 206010014733 Endometrial cancer Diseases 0.000 claims description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 2
- 206010014989 Epidermolysis bullosa Diseases 0.000 claims description 2
- 208000000832 Equine Encephalomyelitis Diseases 0.000 claims description 2
- 201000003542 Factor VIII deficiency Diseases 0.000 claims description 2
- 206010016654 Fibrosis Diseases 0.000 claims description 2
- 241000589602 Francisella tularensis Species 0.000 claims description 2
- 208000009292 Hemophilia A Diseases 0.000 claims description 2
- 208000009889 Herpes Simplex Diseases 0.000 claims description 2
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 2
- 241000713340 Human immunodeficiency virus 2 Species 0.000 claims description 2
- 241000341655 Human papillomavirus type 16 Species 0.000 claims description 2
- 208000001021 Hyperlipoproteinemia Type I Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 208000006404 Large Granular Lymphocytic Leukemia Diseases 0.000 claims description 2
- 241000713666 Lentivirus Species 0.000 claims description 2
- 241000186779 Listeria monocytogenes Species 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 208000032271 Malignant tumor of penis Diseases 0.000 claims description 2
- 201000009906 Meningitis Diseases 0.000 claims description 2
- 208000002030 Merkel cell carcinoma Diseases 0.000 claims description 2
- 208000003445 Mouth Neoplasms Diseases 0.000 claims description 2
- 201000002795 Muckle-Wells syndrome Diseases 0.000 claims description 2
- 241000187479 Mycobacterium tuberculosis Species 0.000 claims description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 2
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims description 2
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims description 2
- 241000588653 Neisseria Species 0.000 claims description 2
- 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 claims description 2
- 208000009905 Neurofibromatoses Diseases 0.000 claims description 2
- 241000187681 Nocardia sp. Species 0.000 claims description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 2
- 206010031096 Oropharyngeal cancer Diseases 0.000 claims description 2
- 206010057444 Oropharyngeal neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 208000002471 Penile Neoplasms Diseases 0.000 claims description 2
- 206010034299 Penile cancer Diseases 0.000 claims description 2
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 claims description 2
- 206010034811 Pharyngeal cancer Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 208000033759 Prolymphocytic T-Cell Leukemia Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 208000002009 Pyruvate Dehydrogenase Complex Deficiency Disease Diseases 0.000 claims description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 241000187562 Rhodococcus sp. Species 0.000 claims description 2
- 241000607142 Salmonella Species 0.000 claims description 2
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 claims description 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 201000008717 T-cell large granular lymphocyte leukemia Diseases 0.000 claims description 2
- 208000000389 T-cell leukemia Diseases 0.000 claims description 2
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 claims description 2
- 208000026651 T-cell prolymphocytic leukemia Diseases 0.000 claims description 2
- 208000002903 Thalassemia Diseases 0.000 claims description 2
- 102000006601 Thymidine Kinase Human genes 0.000 claims description 2
- 108020004440 Thymidine kinase Proteins 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 206010046865 Vaccinia virus infection Diseases 0.000 claims description 2
- 206010047741 Vulval cancer Diseases 0.000 claims description 2
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims description 2
- 241000131891 Yersinia sp. Species 0.000 claims description 2
- 201000006966 adult T-cell leukemia Diseases 0.000 claims description 2
- 201000011165 anus cancer Diseases 0.000 claims description 2
- 229940092524 bartonella henselae Drugs 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 210000001072 colon Anatomy 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 208000022993 cryopyrin-associated periodic syndrome Diseases 0.000 claims description 2
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims description 2
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 claims description 2
- 208000031513 cyst Diseases 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 230000004761 fibrosis Effects 0.000 claims description 2
- 229940118764 francisella tularensis Drugs 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 208000009429 hemophilia B Diseases 0.000 claims description 2
- 208000006454 hepatitis Diseases 0.000 claims description 2
- 231100000283 hepatitis Toxicity 0.000 claims description 2
- 229940127121 immunoconjugate Drugs 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims description 2
- 229940115931 listeria monocytogenes Drugs 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 231100000350 mutagenesis Toxicity 0.000 claims description 2
- 230000035772 mutation Effects 0.000 claims description 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 2
- 239000002105 nanoparticle Substances 0.000 claims description 2
- 201000004931 neurofibromatosis Diseases 0.000 claims description 2
- 201000006958 oropharynx cancer Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 210000004214 philadelphia chromosome Anatomy 0.000 claims description 2
- 208000015445 pyruvate dehydrogenase deficiency Diseases 0.000 claims description 2
- 230000005855 radiation Effects 0.000 claims description 2
- 206010038038 rectal cancer Diseases 0.000 claims description 2
- 201000001275 rectum cancer Diseases 0.000 claims description 2
- 230000001177 retroviral effect Effects 0.000 claims description 2
- 108091092562 ribozyme Proteins 0.000 claims description 2
- 230000001568 sexual effect Effects 0.000 claims description 2
- 201000000849 skin cancer Diseases 0.000 claims description 2
- 241000894007 species Species 0.000 claims description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 2
- 210000000130 stem cell Anatomy 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 230000008685 targeting Effects 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims description 2
- 230000002463 transducing effect Effects 0.000 claims description 2
- 241000712461 unidentified influenza virus Species 0.000 claims description 2
- 241001430294 unidentified retrovirus Species 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 208000007089 vaccinia Diseases 0.000 claims description 2
- 206010046885 vaginal cancer Diseases 0.000 claims description 2
- 208000013139 vaginal neoplasm Diseases 0.000 claims description 2
- 230000009385 viral infection Effects 0.000 claims description 2
- 230000003612 virological effect Effects 0.000 claims description 2
- 201000005102 vulva cancer Diseases 0.000 claims description 2
- 238000004520 electroporation Methods 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000001638 lipofection Methods 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 238000010361 transduction Methods 0.000 claims 1
- 230000026683 transduction Effects 0.000 claims 1
- 238000001890 transfection Methods 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 description 2
- 108700019146 Transgenes Proteins 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000007703 enzymatic ligation assisted by nucleases technique Methods 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 230000007688 immunotoxicity Effects 0.000 description 1
- 231100000386 immunotoxicity Toxicity 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201605586 | 2016-04-01 | ||
| GB1605586.5 | 2016-04-01 | ||
| PCT/SG2017/050183 WO2017171654A1 (en) | 2016-04-01 | 2017-03-31 | Trans-splicing rna (tsrna) |
| JP2018551404A JP7229467B2 (ja) | 2016-04-01 | 2017-03-31 | トランス－スプライシングＲＮＡ（ｔｓＲＮＡ） |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018551404A Division JP7229467B2 (ja) | 2016-04-01 | 2017-03-31 | トランス－スプライシングＲＮＡ（ｔｓＲＮＡ） |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023055809A JP2023055809A (ja) | 2023-04-18 |
| JP2023055809A5 true JP2023055809A5 (https=) | 2023-05-25 |
| JP7570125B2 JP7570125B2 (ja) | 2024-10-21 |
Family
ID=59966148
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018551404A Active JP7229467B2 (ja) | 2016-04-01 | 2017-03-31 | トランス－スプライシングＲＮＡ（ｔｓＲＮＡ） |
| JP2023011523A Active JP7570125B2 (ja) | 2016-04-01 | 2023-01-30 | トランス－スプライシングＲＮＡ（ｔｓＲＮＡ） |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018551404A Active JP7229467B2 (ja) | 2016-04-01 | 2017-03-31 | トランス－スプライシングＲＮＡ（ｔｓＲＮＡ） |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11517583B2 (https=) |
| EP (1) | EP3436590A4 (https=) |
| JP (2) | JP7229467B2 (https=) |
| CN (1) | CN109642241B (https=) |
| AU (1) | AU2017240703B2 (https=) |
| SG (1) | SG11201808538QA (https=) |
| WO (1) | WO2017171654A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021076656A1 (en) * | 2019-10-15 | 2021-04-22 | University Of Massachusetts | Rna editor-enhanced rna trans-splicing |
| EP4100533A1 (en) * | 2020-02-07 | 2022-12-14 | University of Rochester | Ribozyme-mediated rna assembly and expression |
| GB202102118D0 (en) | 2021-02-15 | 2021-03-31 | Cambridge Entpr Ltd | RNA Trans-Splicing molecule |
| WO2022220968A1 (en) * | 2021-04-15 | 2022-10-20 | U1 Bio, Inc. | High efficiency trans-splicing for replacement of targeted rna sequences in human cells |
| GB202108855D0 (en) | 2021-06-21 | 2021-08-04 | Cambridge Entpr Ltd | Methods of eukaryotic gene expression |
| CN113584169B (zh) * | 2021-07-28 | 2024-06-18 | 南京大学 | 一种与肝癌相关的血清tsRNA标志物、探针及其应用 |
| AU2022337146A1 (en) * | 2021-09-03 | 2024-03-14 | Tacit Therapeutics, Inc. | Rna editing via recruitment of spliceosome components |
| EP4466354A2 (en) * | 2022-01-18 | 2024-11-27 | National University of Singapore | Trans-splicing rna (tsrna) |
| EP4522758A4 (en) | 2022-05-13 | 2026-05-06 | Ascidian Therapeutics Inc | Abca4 trans-splicing molecules |
| WO2025085691A1 (en) * | 2023-10-18 | 2025-04-24 | Tacit Therapeutics, Inc. | Trans-splicing nucleic acid molecules and methods of use |
| CN118813791A (zh) * | 2024-09-14 | 2024-10-22 | 中国人民解放军总医院第二医学中心 | 用于诊断寒冷暴露致心肌损伤的生物标志物、试剂盒及应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6280978B1 (en) * | 1995-12-15 | 2001-08-28 | Intronn Holdings, Llc | Methods and compositions for use in spliceosome mediated RNA trans-splicing |
| ATE354957T1 (de) * | 1995-12-15 | 2006-03-15 | Intronn Inc | Durch trans-spaltung erhaltene therapeutische molekule |
| DE10139492B4 (de) * | 2001-08-13 | 2004-06-09 | Eul, Joachim, Dr. | Verfahren zur Reparatur einer mutierten RNA aus einer gendefekten DNA und zum gezielten Abtöten von Tumorzellen durch RNA-Transspleißen sowie Verfahren zum Nachweis von natürlich-transgespleißter zellulärer RNA |
| MXPA04010410A (es) * | 2002-04-30 | 2005-07-05 | Icon Genetics Ag | Vectores de amplificacion basados en trans-empalme. |
| EP1521766B1 (en) * | 2002-06-05 | 2012-11-07 | VIRxSYS Corporation | SPLICEOSOME MEDIATED RNA i TRANS /i -SPLICING AND CORRECTION OF FACTOR VIII GENETIC DEFECTS USING SPLICEOSOME MEDIATED RNA TRANS SPLING |
| EP1579004B1 (en) * | 2002-10-23 | 2010-06-16 | VIRxSYS Corporation | Screening methods for identification of efficient pre-trans-splicing molecules |
| US7192709B2 (en) | 2004-03-15 | 2007-03-20 | Digigenomics Co., Ltd. | Methods for identification, assessment, prevention, and therapy of cancer |
| KR100958293B1 (ko) * | 2008-03-27 | 2010-05-19 | 단국대학교 산학협력단 | 테오필린에 의해 표적 특이적 ｒｎａ 치환 활성이 조절되는알로스테릭 트랜스―스플라이싱 그룹 ｉ 리보자임 |
| KR20110036996A (ko) | 2009-10-05 | 2011-04-13 | 전남대학교산학협력단 | 편평세포암 진단 마커인 ｈｏ-1 및 이의 용도 |
| WO2012056441A1 (en) * | 2010-10-28 | 2012-05-03 | Nanodoc Ltd. | Compositions and methods for specific cleavage of exogenous rna in a cell |
| SG2014012207A (en) * | 2011-08-12 | 2014-05-29 | Virxsys Corp | Compositions and methods for inducing apoptosis |
| KR101293620B1 (ko) | 2011-08-19 | 2013-08-13 | 국립암센터 | 트랜스-스플라이싱 라이보자임 및 암치료 유전자를 포함하는 재조합 아데노바이러스 및 이의 용도 |
| GB201219762D0 (en) * | 2012-11-02 | 2012-12-19 | Bauer Johann | A RNA trans-splicing molecule (RTM) for use in the treatment of cancer |
| KR101429696B1 (ko) * | 2012-11-21 | 2014-08-13 | 국립암센터 | 안전성 및 항암활성이 증가된 재조합 아데노바이러스 및 이의 용도 |
| US20140283156A1 (en) * | 2013-03-14 | 2014-09-18 | Cold Spring Harbor Laboratory | Trans-splicing ribozymes and silent recombinases |
-
2017
- 2017-03-31 EP EP17776008.9A patent/EP3436590A4/en active Pending
- 2017-03-31 SG SG11201808538QA patent/SG11201808538QA/en unknown
- 2017-03-31 AU AU2017240703A patent/AU2017240703B2/en active Active
- 2017-03-31 JP JP2018551404A patent/JP7229467B2/ja active Active
- 2017-03-31 US US16/090,226 patent/US11517583B2/en active Active
- 2017-03-31 WO PCT/SG2017/050183 patent/WO2017171654A1/en not_active Ceased
- 2017-03-31 CN CN201780034177.5A patent/CN109642241B/zh active Active
-
2022
- 2022-11-10 US US17/984,846 patent/US20240075051A1/en active Pending
-
2023
- 2023-01-30 JP JP2023011523A patent/JP7570125B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023055809A5 (https=) | ||
| JP2019509756A5 (https=) | ||
| JP7763277B2 (ja) | 細胞を再プログラム化するための精製された修飾ｒｎａを含むｒｎａ調製物 | |
| US9371511B2 (en) | RNA preparations comprising purified modified RNA for reprogramming cells | |
| JP7570125B2 (ja) | トランス－スプライシングＲＮＡ（ｔｓＲＮＡ） | |
| US20110143397A1 (en) | Rna preparations comprising purified modified rna for reprogramming cells | |
| HK1251259A1 (en) | Rna preparations comprising purified modified rna for reprogramming cells | |
| WO2015192063A1 (en) | Methods and materials for increasing viral vector infectivity | |
| JP2021513866A5 (https=) | ||
| Ivacik et al. | Sustained inhibition of hepatitis B virus replication in vivo using RNAi-activating lentiviruses | |
| WO2023196619A1 (en) | Promoter switches for tissue-specific expression | |
| AU2015215938B2 (en) | RNA preparations comprising purified modified RNA for reprogramming cells | |
| KR20210075126A (ko) | 고도로 콤팩트한 다중-입력 논리 게이트를 코딩하는 핵산 벡터를 사용하여 질환을 치료하는 방법 | |
| US20240018486A1 (en) | Rna preparations comprising purified modified rna for reprogramming cells | |
| WO2025157259A1 (en) | Novel muscle-specific promoters | |
| HK40073099B (zh) | 用於重编程细胞的包含纯化的经修饰的rna的rna制剂 | |
| Bouillé et al. | 538. Transient Non-Viral RNA Delivery Mediated by a Lentiviral Particle | |
| HK40026426A (en) | Rna preparations comprising purified modified rna for reprogramming cells | |
| HK1232910B (en) | Rna preparations comprising purified modified rna for reprogramming cells | |
| HK1232910A1 (en) | Rna preparations comprising purified modified rna for reprogramming cells | |
| HK1176972A (en) | Rna preparations comprising purified modified rna for reprogramming cells |